Karyopharm Therapeutics (KPTI) Return on Capital Employed (2013 - 2025)
Karyopharm Therapeutics (KPTI) reported Return on Capital Employed of 401.0% for Q4 2025, down 25996.0% on a YoY basis from N/an in Q4 2024, and up 48.41% quarter-over-quarter from 777.28% in Q3 2025.
Karyopharm Therapeutics (KPTI) Return on Capital Employed (2013 - 2025) Analysis & Trends
Karyopharm Therapeutics has reported Return on Capital Employed for 13 years, with the latest figure at 401.0% in Q4 2025.
- For the quarter ending Q4 2025, Return on Capital Employed fell 25996.0% year-over-year to 401.0%; the trailing twelve-month figure through Dec 2025 stood at 401.0% (down 25996.0% YoY), and the FY2025 full-year result was 92.79%, up 1563.0% from the prior year.
- Return on Capital Employed for Q4 2025 stood at 401.0%, up from 777.28% in the prior quarter.
- The five-year high for Return on Capital Employed was 33.7% in Q3 2022, with the low at 777.28% in Q3 2025.
- Historically, Return on Capital Employed has averaged 157.82% across 5 years, with a median of 79.81% in 2021.
- Annual changes were most pronounced in 2022 — Return on Capital Employed surged 5678 bps — and 2025, when it slumped 68745 bps.
- Karyopharm Therapeutics' Return on Capital Employed stood at 47.71% in 2021, then sank by 30 bps to 62.15% in 2022, then decreased by 12 bps to 69.75% in 2023, then tumbled by 102 bps to 141.05% in 2024, then sank by 184 bps to 401.0% in 2025.
- The last three Return on Capital Employed figures came in at 401.0% (Q4 2025), 777.28% (Q3 2025), and 674.55% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 450.31% |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 51.73% |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | -107.40% |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -50.43% |
| 10 | Karyopharm Therapeutics | 95.31 Mn | 31.56 Mn | 32.74 Mn | -401.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -401.00% |
| Sep 30, 2025 | -777.28% |
| Jun 30, 2025 | -674.55% |
| Mar 31, 2025 | -213.56% |
| Dec 31, 2024 | -141.05% |
| Sep 30, 2024 | -89.83% |
| Jun 30, 2024 | -86.38% |
| Mar 31, 2024 | -84.27% |
| Dec 31, 2023 | -69.75% |
| Sep 30, 2023 | -56.62% |
| Jun 30, 2023 | -49.50% |
| Mar 31, 2023 | -49.39% |
| Dec 31, 2022 | -62.15% |
| Sep 30, 2022 | -33.70% |
| Jun 30, 2022 | -34.95% |
| Mar 31, 2022 | -34.49% |
| Dec 31, 2021 | -47.71% |
| Sep 30, 2021 | -90.49% |
| Jun 30, 2021 | -83.37% |
| Mar 31, 2021 | -76.25% |